Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase I, Open-Label, Multiple Ascending Dose Study of the Safety and Tolerability of T3011 in advanced Cutaneous or Subcutaneous Malignancies
Commercial Sponsor
Immvira Pharma Co Ltd
Summary
This is a non-randomised dose escalation study. Participants will receive T3011 at the assigned dose level by intratumoural injection commencing on W1D1, and approximately every 14 days thereafter (ie: W3D1, W5D1 etc) for up to 2 years (unless disease progression, unacceptable toxicity, death or withdrawal of consent). The starting dose of T3011 is 1.0 × 10^6 PFU/mL with the volume injected intratumourally based on tumour size, but not exceeding a total of 4 mls for each visit for all tumours combined. The study uses a 3+3 dose escalation design to evaluate escalating doses of T3011 monotherapy. Three additional doses are planned to be tested (1.0 × 10^7, 5.0 × 10^7, and 1 × 10^8 PFU/ml). At any dose level, if no dose-limiting toxicity (DLT) occurs among the first 3 participants, then escalation to the next dose level may proceed if approved by the Safety Review committee (SRC). If 1 DLT occurs in the first 1 to 3 participants, the dose level will expand to a maximum of 6 participants. If no DLT occurs among the additional participants, then escalation to the next dose level may proceed if approved by the SRC. The non-tolerated dose (NTD) is the dose level at which 2 or more participants experience a DLT during the DLT evaluation period. The maximum tolerated dose (MTD) will be defined as the dose level immediately below the NTD. At least 6 participants will be treated at the MTD before expansion to Part 2 (Dose Expansion) with additional participants treated with a dose selected by the SRC.